Browsing Category
Health
Research: Novo Nordisk’s Ozempic can cut back the danger of opioid overdose
A box of Ozempic by Novo Nordisk is seen in a pharmacy in London, United Kingdom on March 8, 2024.Hollie Adams | ReutersNovo NordiskFDA-approved diabetes drug…
Wegovy might subsequent face Medicare drug worth negotiations
Boxes of Novo Nordisk's Ozempic and Wegovy are seen at a pharmacy in London, United Kingdom on March 8, 2024. Hollie Adams | ReutersA version of this…
Novo Nordisk CEO testifies earlier than Senate on weight reduction drug costs
Novo NordiskThe company's top executive faced Senate questioning on Tuesday about the high prices of the company's weight-loss drug Wegovy and…
Safi Biotherapeutics grows blood to fight shortages
Safi employees at work.Courtesy of Safi BiotherapeuticsLast month, the American Red Cross declared a blood shortage after the nationwide supply dropped by more…
Why disputing a medical invoice may help you cut back prices
Consumers often feel like their medical bills are rigid, inflexible and set in stone. But that's not always true: A new study shows that patients can often…
Why Eli Lilly and Palo Alto Networks each profit from their rivals’ information
Every weekday, CNBC Investing Club with Jim Cramer publishes the Homestretch -- an actionable afternoon update, just in time for the final hour of trading on…
FTC sues drug brokers for allegedly exaggerating insulin costs
Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Committee in the Rayburn House Office Building in Washington,…
Race for radiopharmaceuticals intensifies: Pharmaceutical firms chase Novartis
Pharmaceutical companies believe that direct radiation of tumors will be the next big breakthrough in the fight against cancer. Bristol-Myers Squibb,…
23andMe Impartial Administrators Resign from Board: Learn CEO Memo
Anne Wojcicki, co-founder and CEO of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, USA, on Friday, March 10, 2023. Jordan…
Novartis just isn’t collaborating within the hype surrounding weight-loss medicine, says CEO
The CEO of Novartis said on Wednesday that the Swiss pharmaceutical giant does not plan to participate in the "hype" surrounding weight-loss drugs, but would…